
Pieter Gillard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1969832/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials. Transplantation, 2022, 106, 734-748.	O.5	6
2	Relationship Between Time in Range, Glycemic Variability, HbA1c, and Complications in Adults With Type 1 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e570-e581.	1.8	39
3	Pancreas Islet Cell-Specific Antibody Detection by ELISA. journal of applied laboratory medicine, The, 2022, 7, 66-74.	0.6	4
4	Function and composition of pancreatic islet cell implants in omentum of type 1 diabetes patients. American Journal of Transplantation, 2022, 22, 927-936.	2.6	10
5	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care, 2022, 45, e888-e897.	4.3	20
6	Diabetic Ketoacidosis After Sodium–Glucose Cotransporter Inhibitor Initiation Under Advanced Hybrid Closed-Loop Therapy in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2022, 24, 516-519.	2.4	4
7	Ladarixin, an inhibitor of the interleukinâ€8 receptors <scp>CXCR1</scp> and <scp>CXCR2</scp> , in newâ€onset type 1 diabetes: A multicentre, randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2022, 24, 1840-1849.	2.2	17
8	Utility of Islet Cell Preparations From Donor Pancreases After Euthanasia. Cell Transplantation, 2022, 31, 096368972210961.	1.2	1
9	A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes. Diabetologia, 2021, 64, 313-324.	2.9	27
10	Formation of amyloid in encapsulated human pancreatic and human stem cell-generated beta cell implants. American Journal of Transplantation, 2021, 21, 2090-2099.	2.6	2
11	Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]. Diabetologia, 2021, 64, 935-938.	2.9	4
12	Diabetes Knowledge and Metabolic Control in Type 1 Diabetes Starting With Continuous Glucose Monitoring: FUTURE-PEAK. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3037-e3048.	1.8	10
13	726-P: Glucose Control Using Fast-Acting Insulin Aspart in a Real-World Setting: A One-Year Multicenter Study in People with Type 1 Diabetes Using Continuous Glucose Monitoring. Diabetes, 2021, 70, 726-P.	0.3	0
14	Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. Lancet, The, 2021, 397, 2275-2283.	6.3	100
15	189-OR: FIDELIO-DKD Study: Analysis of Effects of Finerenone by Baseline A1C. Diabetes, 2021, 70, .	0.3	0
16	Glucose control using fastâ€acting insulin aspart in a realâ€world setting: A <scp>1</scp> â€year, twoâ€centre study in people with type <scp>1</scp> diabetes using continuous glucose monitoring. Diabetes, Obesity and Metabolism, 2021, 23, 2716-2727.	2.2	11
17	Genetic variation at ERBB3/IKZF4 and sexual dimorphism in epitope spreading in single autoantibody-positive relatives. Diabetologia, 2021, 64, 2511-2516.	2.9	6
18	Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT. Diabetologia, 2021, 64, 2725-2730.	2.9	3

#	Article	IF	CITATIONS
19	Delayed Bleeding of the Transplant Duodenum After Simultaneous Kidney-pancreas Transplantation: Case Series. Transplantation, 2020, 104, 184-189.	0.5	3
20	Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study. Diabetes Care, 2020, 43, 389-397.	4.3	163
21	Intermittently scanned continuous glucose monitoring is associated with high satisfaction but increased HbA1c and weight in wellâ€controlled youth with type 1 diabetes. Pediatric Diabetes, 2020, 21, 1465-1474.	1.2	8
22	Sustained Impact of Real-time Continuous Glucose Monitoring in Adults With Type 1 Diabetes on Insulin Pump Therapy: Results After the 24-Month RESCUE Study. Diabetes Care, 2020, 43, 3016-3023.	4.3	28
23	Use of Culture to Reach Metabolically Adequate Beta-cell Dose by Combining Donor Islet Cell Isolates for Transplantation in Type 1 Diabetes Patients. Transplantation, 2020, 104, e295-e302.	0.5	1
24	The nephrological perspective on SGLT-2 inhibitors in type 1 diabetes. Diabetes Research and Clinical Practice, 2020, 170, 108462.	1.1	10
25	Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). Diabetologia, 2020,	2.9	102
26	Glucose management for exercise using continuous glucose monitoring (<scp>CGM</scp>) and intermittently scanned <scp>CGM</scp> (<scp>isCGM</scp>) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (<scp>EASD</scp>) and of the International Society for Pediatric and Adolescent Diabetes (<scp>ISPAD</scp>) endorsed by <scp>.</scp>	1.2	46
27	Pediatric Diabetes, 2020, 21, 1375-1393. No Evidence of Increased Hospitalization Rate for COVID-19 in Community-Dwelling Patients With Type 1 Diabetes. Diabetes Care, 2020, 43, e118-e119.	4.3	24
28	Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2020, 8, 845-854.	5.5	46
29	Insulitis and lymphoid structures in the islets of Langerhans of a 66-year-old patient with long-standing type 1 diabetes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 478, 1209-1214.	1.4	6
30	Use of hyperglycemic clamp to assess pancreatectomy and islet cell autotransplant in patient with heterotaxy syndrome and dorsal pancreas agenesis leading to chronic pancreatitis. American Journal of Transplantation, 2020, 20, 3662-3666.	2.6	1
31	Pancreatic Insufficiency and an Absent Gallbladder: Connecting the Dots. Gastroenterology, 2020, 159, e8-e9.	0.6	0
32	249-OR: A Randomized, Double-Blind Phase 2 Trial of the CXCR1/2 Inhibitor Ladarixin in Adult Patients with New-Onset Type 1 Diabetes. Diabetes, 2020, 69, .	0.3	2
33	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.	6.3	408
34	Glycaemic control on nutritional support: finding stability in unstable times. Lancet Diabetes and Endocrinology,the, 2019, 7, 330-331.	5.5	0
35	Occurrence of Diabetic Nephropathy After Renal Transplantation Despite Intensive Glycemic Control: An Observational Cohort Study. Diabetes Care, 2019, 42, 625-634.	4.3	19
36	Combined Analysis of GAD65, miR-375, and Unmethylated Insulin DNA Following Islet Transplantation in Patients With T1D. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 451-460.	1.8	15

#	Article	IF	CITATIONS
37	Artificial Pancreas Systems for People With Type 2 Diabetes: Conception and Design of the European CLOSE Project. Journal of Diabetes Science and Technology, 2019, 13, 261-267.	1.3	13
38	1367-P: Effect of Nationwide Reimbursement of Sensor-Augmented Pump (SAP) Therapy in a Paediatric Type 1 Diabetes (T1D) Population on HbA1c, Hypoglycaemia, and Quality of Life (QoL) According to Age Groups in the RESCUE-Paediatrics Study. Diabetes, 2019, 68, 1367-P.	0.3	0
39	Stem-cell-based Therapies for Improving Islet Transplantation Outcomes in Type 1 Diabetes. Current Diabetes Reviews, 2018, 14, 3-13.	0.6	11
40	Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1224-1232.	1.8	125
41	SLC30A8 polymorphism and BMI complement HLA-A*24 as risk factors for poor graft function in islet allograft recipients. Diabetologia, 2018, 61, 1623-1632.	2.9	1
42	Accuracy and precision of flash glucose monitoring sensors inserted into the abdomen and upper thigh compared with the upper arm. Diabetes, Obesity and Metabolism, 2018, 20, 1503-1507.	2.2	25
43	Cover Image, Volume 20, Issue 6. Diabetes, Obesity and Metabolism, 2018, 20, i-i.	2.2	Ο
44	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the) Tj ETQq0 0	0 rg₿Ţ /Ov	erlock 10 Tf 5
45	Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes—DEPICT-2 Study. Diabetes, 2018, 67, 213-OR.	0.3	11
46	Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nature Reviews Endocrinology, 2017, 13, 385-399.	4.3	170
47	Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. Transplantation, 2017, 101, 2218-2227.	0.5	3
48	Identification of Donor Origin and Condition of Transplanted Islets in Situ in the Liver of a Type 1 Diabetic Recipient. Cell Transplantation, 2017, 26, 1-9.	1.2	1
49	Drug–drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus. Transplantation Reviews, 2017, 31, 69-77.	1.2	37
50	Serum Cytokines as Biomarkers in Islet Cell Transplantation for Type 1 Diabetes. PLoS ONE, 2016, 11, e0146649.	1.1	12
51	Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio. PLoS ONE, 2016, 11, e0166702.	1.1	14
52	<i>HLA-A*24</i> Carrier Status and Autoantibody Surges Posttransplantation Associate With Poor Functional Outcome in Recipients of an Islet Allograft. Diabetes Care, 2016, 39, 1060-1064.	4.3	11
53	Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 461-469.	1.8	23
54	Hemoglobin A2-Leuven (α2δ2 143(H21) His>Asp): a novel delta-chain variant potentially interfering in hemoglobin A1c measurement using cation exchange HPLC. Clinical Chemistry and Laboratory Medicine, 2016, 54, e161-3.	1.4	5

#	Article	IF	CITATIONS
55	Hyperglycemic Clamp and Oral Glucose Tolerance Test for 3-Year Prediction of Clinical Onset in Persistently Autoantibody-Positive Offspring and Siblings of Type 1 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 551-560.	1.8	10
56	Plasma GAD65, a Marker for Early β-Cell Loss After Intraportal Islet Cell Transplantation in Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2314-2321.	1.8	22
57	Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes. Diabetologia, 2015, 58, 2753-2764.	2.9	15
58	Bariatric Surgery Induces Weight Loss but Does Not Improve Glycemic Control in Patients With Type 1 Diabetes. Diabetes Care, 2014, 37, e173-e174.	4.3	34
59	Early Alteration of Kidney Function in Nonuremic Type 1 Diabetic Islet Transplant Recipients Under Tacrolimus-Mycophenolate Therapy. Transplantation, 2014, 98, 451-457.	0.5	12
60	In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions. Diabetologia, 2013, 56, 1964-1970.	2.9	15
61	Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. Diabetologia, 2013, 56, 1605-1614.	2.9	190
62	<i>HLA-A*24</i> Is an Independent Predictor of 5-Year Progression to Diabetes in Autoantibody-Positive First-Degree Relatives of Type 1 Diabetic Patients. Diabetes, 2013, 62, 1345-1350.	0.3	20
63	Minimal Functional β-Cell Mass in Intraportal Implants That Reduces Glycemic Variability in Type 1 Diabetic Recipients. Diabetes Care, 2013, 36, 3483-3488.	4.3	26
64	Predictive Factors of Allosensitization After Immunosuppressant Withdrawal in Recipients of Long-Term Cultured Islet Cell Grafts. Transplantation, 2013, 96, 162-169.	0.5	9
65	Immune responses against islet allografts during tapering of immunosuppression - A pilot study in 5 subjects. Clinical and Experimental Immunology, 2012, , no-no.	1.1	0
66	lmmune responses against islet allografts during tapering of immunosuppression – a pilot study in 5 subjects. Clinical and Experimental Immunology, 2012, 169, 190-198.	1.1	22
67	Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients. Clinical and Experimental Immunology, 2012, 171, 82-90.	1.1	41
68	Otelixizumab in the treatment of Type 1 diabetes mellitus. Immunotherapy, 2011, 3, 1303-1316.	1.0	13
69	Arresting type 1 diabetes after diagnosis: GAD is not enough. Lancet, The, 2011, 378, 291-292.	6.3	12
70	Comparative Evaluation of Simple Indices of Graft Function After Islet Transplantation. Transplantation, 2011, 92, 815-821.	0.5	36
71	Immune and cell therapy in type 1 diabetes: too little too late?. Expert Opinion on Biological Therapy, 2011, 11, 609-621.	1.4	2
72	Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients. Diabetologia, 2010, 53, 36-44.	2.9	23

#	Article	IF	CITATIONS
73	Graves Hyperthyroidism After Stopping Immunosuppressive Therapy in Type 1 Diabetic Islet Cell Recipients With Pretransplant TPO Autoantibodies. Diabetes Care, 2009, 32, 1817-1819.	4.3	19
74	Differences in Baseline Lymphocyte Counts and Autoreactivity Are Associated With Differences in Outcome of Islet Cell Transplantation in Type 1 Diabetic Patients. Diabetes, 2009, 58, 2267-2276.	0.3	96
75	Allograft-Specific Cytokine Profiles Associate with Clinical Outcome After Islet Cell Transplantation. American Journal of Transplantation, 2009, 9, 382-388.	2.6	68
76	Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clinical and Experimental Immunology, 2009, 156, 141-148.	1.1	41
77	Functional β-Cell Mass and Insulin Sensitivity Is Decreased in Insulin-Independent Pancreas-Kidney Recipients. Transplantation, 2009, 87, 402-407.	0.5	18
78	Cholestatic liver disease in longâ€ŧerm infantile nephropathic cystinosis. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, e428-31.	1.4	15
79	Comparison of Sirolimus Alone With Sirolimus Plus Tacrolimus in Type 1 Diabetic Recipients of Cultured Islet Cell Grafts. Transplantation, 2008, 85, 256-263.	0.5	33
80	Cellular Islet Autoimmunity Associates with Clinical Outcome of Islet Cell Transplantation. PLoS ONE, 2008, 3, e2435.	1.1	172
81	Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17444-17449.	3.3	166
82	Post-transplant lymphoma of the pancreatic allograft in a kidney-pancreas transplant recipient: a misleading presentation. Nephrology Dialysis Transplantation, 2006, 21, 3306-3310.	0.4	7
83	Feasibility, Safety, and Efficacy of Percutaneous Transhepatic Injection of β-Cell Grafts. Journal of Vascular and Interventional Radiology, 2005, 16, 1693-1697.	0.2	26
84	Â-Cell Transplantation Restores Metabolic Control and Quality of Life in a Patient With Subcutaneous Insulin Resistance. Diabetes Care, 2004, 27, 2243-2244.	4.3	15